418 related articles for article (PubMed ID: 17257431)
1. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
2. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
[TBL] [Abstract][Full Text] [Related]
3. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
7. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
Ooi T; Barnetson RS; Zhuang L; McKane S; Lee JH; Slade HB; Halliday GM
Br J Dermatol; 2006 Jan; 154(1):72-8. PubMed ID: 16403097
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Quist SR; Gollnick HP
Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
[TBL] [Abstract][Full Text] [Related]
13. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Gebauer K; Shumack S; Cowen PS
Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
[TBL] [Abstract][Full Text] [Related]
14. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
Strohal R; Kerl H; Schuster L
J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
[TBL] [Abstract][Full Text] [Related]
15. Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
Rowlands MA; Giacometti JN; Servat J; Materin MA; Levin F
Ophthalmic Plast Reconstr Surg; 2017; 33(1):e21-e23. PubMed ID: 25853505
[TBL] [Abstract][Full Text] [Related]
16. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
Shaffelburg M
J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod cream in the treatment of actinic keratoses.
Persaud A; Lebwohl M
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S236-9. PubMed ID: 12271285
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
20. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
Yu A; Tanizaki H; Kokunai Y; Kaneda K; Sugimoto A; Otsuka T; Kurokawa T; Moriwaki S
J Dermatol; 2018 Apr; 45(4):496-500. PubMed ID: 29265412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
